Suppr超能文献

高密度脂蛋白通过溶血磷脂受体S1P3诱导一氧化氮依赖性血管舒张。

HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3.

作者信息

Nofer Jerzy-Roch, van der Giet Markus, Tölle Markus, Wolinska Iza, von Wnuck Lipinski Karin, Baba Hideo A, Tietge Uwe J, Gödecke Axel, Ishii Isao, Kleuser Burkhard, Schäfers Michael, Fobker Manfred, Zidek Walter, Assmann Gerd, Chun Jerold, Levkau Bodo

机构信息

Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität, Münster, Germany.

出版信息

J Clin Invest. 2004 Feb;113(4):569-81. doi: 10.1172/JCI18004.

Abstract

HDL is a major atheroprotective factor, but the mechanisms underlying this effect are still obscure. HDL binding to scavenger receptor-BI has been shown to activate eNOS, although the responsible HDL entities and signaling pathways have remained enigmatic. Here we show that HDL stimulates NO release in human endothelial cells and induces vasodilation in isolated aortae via intracellular Ca2+ mobilization and Akt-mediated eNOS phosphorylation. The vasoactive effects of HDL could be mimicked by three lysophospholipids present in HDL: sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF). All three elevated intracellular Ca2+ concentration and activated Akt and eNOS, which resulted in NO release and vasodilation. Deficiency of the lysophospholipid receptor S1P3 (also known as LPB3 and EDG3) abolished the vasodilatory effects of SPC, S1P, and LSF and reduced the effect of HDL by approximately 60%. In endothelial cells from S1P3-deficient mice, Akt phosphorylation and Ca2+ increase in response to HDL and lysophospholipids were severely reduced. In vivo, intra-arterial administration of HDL or lysophospholipids lowered mean arterial blood pressure in rats. In conclusion, we identify HDL as a carrier of bioactive lysophospholipids that regulate vascular tone via S1P3-mediated NO release. This mechanism may contribute to the vasoactive effect of HDL and represent a novel aspect of its antiatherogenic function.

摘要

高密度脂蛋白(HDL)是一种主要的抗动脉粥样硬化保护因子,但其作用机制仍不清楚。尽管负责的HDL实体和信号通路仍然不明,但已表明HDL与清道夫受体BI结合可激活内皮型一氧化氮合酶(eNOS)。在这里,我们表明HDL刺激人内皮细胞释放一氧化氮(NO),并通过细胞内钙离子动员和Akt介导的eNOS磷酸化在离体主动脉中诱导血管舒张。HDL的血管活性作用可被HDL中存在的三种溶血磷脂模拟:鞘氨醇磷酸胆碱(SPC)、鞘氨醇-1-磷酸(S1P)和溶血硫酸脑苷脂(LSF)。这三种物质均提高细胞内钙离子浓度并激活Akt和eNOS,从而导致NO释放和血管舒张。溶血磷脂受体S1P3(也称为LPB3和EDG3)的缺乏消除了SPC、S1P和LSF的血管舒张作用,并使HDL的作用降低了约60%。在来自S1P3缺陷小鼠的内皮细胞中,HDL和溶血磷脂刺激引起的Akt磷酸化和钙离子增加显著减少。在体内,动脉内给予HDL或溶血磷脂可降低大鼠的平均动脉血压。总之,我们确定HDL是生物活性溶血磷脂的载体,其通过S1P3介导的NO释放调节血管张力。这一机制可能有助于HDL的血管活性作用,并代表其抗动脉粥样硬化功能的一个新方面。

相似文献

引用本文的文献

4
Sphingolipids and Chronic Kidney Disease.鞘脂与慢性肾脏病
J Clin Med. 2024 Aug 26;13(17):5050. doi: 10.3390/jcm13175050.
7
Ying and Yang of Ceramide in the Vascular Endothelium.血管内皮细胞中神经酰胺的阴阳两面。
Arterioscler Thromb Vasc Biol. 2024 Aug;44(8):1725-1736. doi: 10.1161/ATVBAHA.124.321158. Epub 2024 Jun 20.

本文引用的文献

1
Lysophospholipid receptors: signaling and biology.溶血磷脂受体:信号传导与生物学
Annu Rev Biochem. 2004;73:321-54. doi: 10.1146/annurev.biochem.73.011303.073731.
5
Sphingosine 1-phosphate and control of vascular tone.鞘氨醇-1-磷酸与血管张力的调控
Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2045-52. doi: 10.1152/ajpheart.01089.2002.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验